Lancet: The dulutvir-emtricitabine-tenofovir alafenamide treatment program is currently the safest and most effective HIV treatment program for pregnant women

For HIV- infected pregnant women, antiretroviral therapy (ART) during pregnancy is very important for maternal health and prevention of perinatal HIV transmission.

Infection prevention

Recently, researchers compared three ART treatment options: dulutvir-emtricitabine-tenofovir alafenamide, dulutvir-emtricitabine-tenofovir disoproxil and The efficacy and safety of favirenz-emtricitabine-tenofovir disoproxil on HIV-positive pregnant women .

Recently, researchers compared three ART treatment options: dulutvir-emtricitabine-tenofovir alafenamide, dulutvir-emtricitabine-tenofovir disoproxil and Efficacy and safety of fevirenyl-emtricitabine-tenofovir disoproxil on HIV-positive pregnant women.

This multi-center, randomized, controlled phase III clinical study was carried out in 22 clinical centers in 9 countries.

643 pregnant women participated in the study, including 217 in the dulutvir-emtricitabine-tenofovir alafenamide group and 215 in the dulutvir-emtricitabine-tenofovir disoproxil group , Efavirenz-emtricitabine-tenofovir disoproxil 211 people.

Of the 405 patients who received the dulutvir-containing regimen, 385 (98%) achieved viral suppression, and among the 200 patients who received the efavirenz regimen, 182 (91%) achieved viral suppression.

HIV inhibition rate between groups

Studies have concluded that for HIV-positive pregnant women, antiretroviral treatment programs containing dulutvir have advantages in suppressing the virus, preventing mother-to-child transmission during delivery, reducing adverse pregnancy outcomes and the incidence of adverse events between mothers and infants.

For HIV-positive pregnant women, antiretroviral treatment regimens containing dulutvir have advantages in suppressing the virus, preventing mother-to-child transmission during delivery, reducing adverse pregnancy outcomes and the incidence of maternal and infant adverse events.

Original source:

Shahin Lockman et al.

Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy controlled regimens started in pregnancy (IMPAACT 2010/VESTED): a, randomised, open-label phase 3 trial.


Leave a message here